Figure 9 — Validation and identification of anoikis-related lncRNA signatures for improving prognosis in clear cell renal cell carcinoma

Research Paper|Volume 16, Issue 4|pp. 3915–3933

Validation and identification of anoikis-related lncRNA signatures for improving prognosis in clear cell renal cell carcinoma

Back to articleFigure 9(9 of 9)

100%

Figure 9.Drug sensitivity exploration. The distribution of IC50 in (A) Sorafenib. (B) Sunitinib. (C) Saracatinib. (D) Paclitaxel. (E) Dasatinib. (F) Imatinib. (G) Rapamycin. (H) Erlotinib. (I–P) Correlation analysis of ARLs prognostic signature and drug sensitivity (IC50).